Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | CYCS | P99999 | 4/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | TOP1 | P11387 | 3/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19296931 | 0.90 | ABCG2 (0.36) | ABCG2DHODHCYCSESR1ESR2 | |
| SCHEMBL19289802 | 0.86 | HSP90AA1 (0.36) | DHODHTOP1ENPP2 | |
| SCHEMBL19854867 | 0.84 | TERT (0.38) | DHODHCYCSTOP1 | |
| SCHEMBL19289584 | 0.84 | ESR1 (0.34) | DHODHCYCSESR1ESR2 | |
| SCHEMBL19278954 | 0.84 | ESR1 (0.34) | DHODHCYCSESR1ESR2 | |
| SCHEMBL19278953 | 0.84 | ESR1 (0.34) | DHODHCYCSESR1ESR2 | |
| SCHEMBL31310041 | 0.84 | ESR1 (0.34) | DHODHCYCSESR1ESR2 | |
| SCHEMBL19289582 | 0.83 | DHODH (0.33) | DHODHCYCSTOP1ENPP2 | |
| SCHEMBL19296902 | 0.81 | DHODH (0.36) | DHODHCYCSTOP1ENPP2 | |
| SCHEMBL19278970 | 0.81 | HSP90AA1 (0.36) | DHODHTOP1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738059-B2 | Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2020-08-11 | — | — | US | disclosed |
| US-20170247384-A1 | CONJUGATES OF PORPHYRINOID PHOTOSENSITIZERS AND GLYCEROL-BASED POLYMERS FOR PHOTODYNAMIC THERAPY | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738059-B2 | Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy | FPGS, PPOX, UROD | ABCG2 801/4885DHODH 191/4885CYCS 2671/4885 |
| US-20170247384-A1 | CONJUGATES OF PORPHYRINOID PHOTOSENSITIZERS AND GLYCEROL-BASED POLYMERS FOR PHOTODYNAMIC THERAPY | FPGS, PPOX, UROD | ABCG2 801/4885DHODH 191/4885CYCS 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.